請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73666
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 盧子彬(Tzu-Pin Lu) | |
dc.contributor.author | Meng-Chun Wu | en |
dc.contributor.author | 吳孟駿 | zh_TW |
dc.date.accessioned | 2021-06-17T08:07:40Z | - |
dc.date.available | 2021-08-20 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-18 | |
dc.identifier.citation | 1. Lim, S.S., et al., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012. 380(9859): p. 2224-2260.
2. Kjeldsen, S.E., Hypertension and cardiovascular risk: General aspects. Pharmacol Res, 2018. 129: p. 95-99. 3. Alberti, K.G., et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009. 120(16): p. 1640-1645. 4. Launer, L.J., et al., Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging, 2000. 21(1): p. 49-55. 5. Kearney, P.M., et al., Global burden of hypertension: analysis of worldwide data. Lancet, 2005. 365(9455): p. 217-223. 6. Su, T.C., et al., Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens, 2008. 26(3): p. 600-606. 7. Czuriga-Kovacs, K.R., D. Czuriga, and L. Csiba, Influence of Hypertension, Alone and in Combination with Other Vascular Risk Factors on Cognition. CNS Neurol Disord Drug Targets, 2016. 15(6): p. 690-698. 8. Lee, M.R., Y.H. Lim, and Y.C. Hong, Causal association of body mass index with hypertension using a Mendelian randomization design. Medicine (Baltimore), 2018. 97(30): p. e11252. 9. Kunutsor, S.K., et al., Circulating Total Bilirubin and Future Risk of Hypertension in the General Population: The Prevention of Renal and Vascular End-Stage Disease (PREVEND) Prospective Study and a Mendelian Randomization Approach. J Am Heart Assoc, 2017. 6(11). 10. Ahluwalia, M. and S. Bangalore, Management of hypertension in 2017: targets and therapies. Curr Opin Cardiol, 2017. 32(4): p. 413-421. 11. Hvas, A.M. and E.J. Favaloro, Platelet Function Analyzed by Light Transmission Aggregometry. Methods Mol Biol, 2017. 1646: p. 321-331. 12. Sachdev, R., et al., Establishing biological reference intervals for novel platelet parameters (immature platelet fraction, high immature platelet fraction, platelet distribution width, platelet large cell ratio, platelet-X, plateletcrit, and platelet distribution width) and their correlations among each other. Indian J Pathol Microbiol, 2014. 57(2): p. 231-235. 13. Wille, K., P. Sadjadian, and M. Griesshammer, [Thrombocytosis and thrombocytopenia - background and clinical relevance]. Dtsch Med Wochenschr, 2017. 142(23): p. 1732-1743. 14. Thachil, J. and T.E. Warkentin, How do we approach thrombocytopenia in critically ill patients? Br J Haematol, 2017. 177(1): p. 27-38. 15. Gill, D., et al., Genetically Determined Platelet Count and Risk of Cardiovascular Disease. Arterioscler Thromb Vasc Biol, 2018. 38(12): p. 2862-2869. 16. Zhu, Y., et al., Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis. Cancer Epidemiol Biomarkers Prev, 2019. 28(5): p. 935-942. 17. Packham, M.A., Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol, 1994. 72(3): p. 278-284. 18. Koupenova, M., et al., Thrombosis and platelets: an update. Eur Heart J, 2017. 38(11): p. 785-791. 19. Martin, J.F., et al., Changes in volume and density of platelets in myocardial infarction. Br Med J (Clin Res Ed), 1983. 287(6390): p. 456-459. 20. Goli, R.R., et al., Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications. Curr Atheroscler Rep, 2017. 19(12): p. 56. 21. Gueyffier, F., et al., Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med, 1997. 126(10): p. 761-767. 22. Yang, K., et al., An association of platelet indices with blood pressure in Beijing adults: Applying quadratic inference function for a longitudinal study. Medicine (Baltimore), 2016. 95(39): p. e4964. 23. Gang, L., et al., Association between mean platelet volume and hypertension incidence. Hypertens Res, 2017. 40(8): p. 779-784. 24. Fewell, Z., G. Davey Smith, and J.A. Sterne, The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol, 2007. 166(6): p. 646-655. 25. Smith, G.D. and S. Ebrahim, 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol, 2003. 32(1): p. 1-22. 26. Kunicki, T.J., S.A. Williams, and D.J. Nugent, Genetic variants that affect platelet function. Curr Opin Hematol, 2012. 19(5): p. 371-379. 27. Burgess, S. and S.G. Thompson, Use of allele scores as instrumental variables for Mendelian randomization. Int J Epidemiol, 2013. 42(4): p. 1134-1144. 28. Zheng, J., et al., Recent Developments in Mendelian Randomization Studies. Curr Epidemiol Rep, 2017. 4(4): p. 330-345. 29. Fan, C.T., J.C. Lin, and C.H. Lee, Taiwan Biobank: a project aiming to aid Taiwan's transition into a biomedical island. Pharmacogenomics, 2008. 9(2): p. 235-246. 30. Chen, C.H., et al., Population structure of Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan Biobank project. Hum Mol Genet, 2016. 25(24): p. 5321-5331. 31. Emdin, C.A., A.V. Khera, and S. Kathiresan, Mendelian Randomization. Jama, 2017. 318(19): p. 1925-1926. 32. Lawlor, D.A., et al., Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med, 2008. 27(8): p. 1133-1163. 33. Bowden, J., et al., Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol, 2016. 40(4): p. 304-314. 34. Vinholt, P.J., et al., Platelet count is associated with cardiovascular disease, cancer and mortality: A population-based cohort study. Thromb Res, 2016. 148: p. 136-142. 35. Cetin, M., et al., Increased platelet distribution width is associated with ST-segment elevation myocardial infarction and thrombolysis failure. Angiology, 2014. 65(8): p. 737-743. 36. Inanc, T., et al., The mean platelet volume in patients with non-dipper hypertension compared to dippers and normotensives. Blood Press, 2010. 19(2): p. 81-85. 37. Surgit, O., et al., Assessment of Mean Platelet Volume in Patients with Resistant Hypertension, Controlled Hypertension and Normotensives. Eurasian J Med, 2015. 47(2): p. 79-84. 38. Varol, E., et al., Mean platelet volume in patients with prehypertension and hypertension. Clin Hemorheol Microcirc, 2010. 45(1): p. 67-72. 39. Siess, W., Molecular mechanisms of platelet activation. Physiol Rev, 1989. 69(1): p. 58-178. 40. Dockrell, M.E., et al., Platelet aggregation in young men with contrasting predisposition to high blood pressure. Am J Hypertens, 1999. 12(2 Pt 1): p. 115-9. 41. Holmsen, H., Platelet metabolism and activation. Semin Hematol, 1985. 22(3): p. 219-40. 42. Schatzkin, A., et al., Mendelian randomization: how it can--and cannot--help confirm causal relations between nutrition and cancer. Cancer Prev Res (Phila), 2009. 2(2): p. 104-113. 43. Pierce, B.L., H. Ahsan, and T.J. Vanderweele, Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol, 2011. 40(3): p. 740-752. 44. Fortier, I., et al., Maelstrom Research guidelines for rigorous retrospective data harmonization. Int J Epidemiol, 2017. 46(1): p. 103-105. 45. Hartwig, F.P., et al., Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int J Epidemiol, 2016. 45(6): p. 1717-1726. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73666 | - |
dc.description.abstract | 中文摘要
背景 從臨床上及生物機制角度上,血小板都在增加血栓形成的傾向中扮演關鍵的角色,並且已被證實和心血管疾病有關。過去的研究指出,血小板和高血壓有相關,然而這些研究可能受到干擾偏差或是研究設計上的限制無法達成因果推論。另外,過往也缺乏在血小板指標中重要的血小板數量與高血壓的相關性研究。我們採用和血小板數量相關的單核苷酸多態性為工具變項,執行遺傳風險評分孟德爾隨機化,藉此推論血小板數量和高血壓的因果關係。 材料及方法 在我們的研究中,我們隨機從台灣人體生物資料庫抽取15,996位年齡介於30歲到70歲的台灣漢民族作為我們的研究對象。暴露因子及臨床結果分別為第一次量測的血小板數量及經定義的高血壓。包含有646,735單核苷酸多態性在內的基因資料,所有分析的資料皆取自相同的來源。我們設定4個不同的情境取得適合的單核苷酸多態性並降低干擾因子的干擾。我們利用計算遺傳風險評分及以權重中位數模型建立的遺傳風險評分孟德爾隨機化來推論血小板和高血壓間的因果關係。 結果 在相關性分析的部份,我們分別在只有納入性別和年齡當作共變項的羅吉斯回歸以及所有變數納入作為共變項的羅吉斯回歸都得到血小板數量和高血壓有正向且顯著的相關性(p值分別為3.8e-10和2.85e-3)。納入大於2個基因變異作為工具變項的所有情境中,遺傳風險評分孟德爾隨機化亦得到一致正向且顯著(p值< 0.05)的結果。 結論 我們有足夠的統計證據說明血小板數量和高血壓的因果關係。在未來,血小板可以做為高血壓的一項危險因子以作為臨床以及預防性治療開發的相關應用。 關鍵字:孟德爾隨機化,遺傳風險評分,血小板數量,高血壓,台灣人體生物資料庫,因果推論 | zh_TW |
dc.description.abstract | ABSTARCT
BACKGROUND Platelet has a crucial role in the increasing thrombotic tendency from both clinical and biological perspectives, and has already been reported correlated to cardiovascular diseases. Some of the previous studies showed that platelet has correlation to hypertension as well, however, with some confounding bias or design restrictions so that the causal inference didn’t succeed. Also, there would be absence in the form of platelet count, which is one of the important platelet indices, in the previous studies. We have utilized several single nucleotide polymorphisms (SNPs) related to platelet count as instrumental variables to perform genetic risk score Mendelian randomization to make the causal inference of platelet count on hypertension. MATERIAL AND METHODS There were 15,996 healthy Taiwanese Han individuals aging from years 30 to 70 randomly picked up from the Taiwan Biobank project in our study. The baseline of platelet count and hypertension were used as an exposure and an outcome, and the clinical data and genomic data with 646,735 SNPs were all coming from the same dataset. We set 4 different scenarios to choose the appropriate SNPs and eliminated the interventions from confounding factors. The genetic risk score development and the further genetic risk score Mendelian randomization in weighted-median model was then executed to elucidate the causal relationship of platelet count on hypertension. RESULTS There was significantly positive relationship of platelet count on hypertension with only age and sex (p-value = 3.80 e-10) and all the confounding included in logistic regression analysis (p-value = 2.85 e-3). The positive causal relationships between platelet count and hypertension were also consistently statistically significant (p-value < 0.05) in 3 different scenarios with more than 2 SNPs as instrumental variables in genetic risk score Mendelian randomization. CONCLUSION Our study had enough evidence to state that platelet count had causal relationship on hypertension. Platelet count could be taken as the risk factor of the hypertension, and then related clinical applications and preventive therapeutic treatments could be considered in the near future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:07:40Z (GMT). No. of bitstreams: 1 ntu-108-R06849011-1.pdf: 1813948 bytes, checksum: 7d1165b79908af7db6ca415efb4bf52f (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 致謝 I
中文摘要 II ABSTARCT IV CHAPTER 1: BACKGROUND 1 CHAPTER 2: MATERIAL AND METHODS 5 Study population 5 Individual quality controls 6 Genotyping quality controls 6 Scenario settings 7 Selection of genetic loci 8 Approach with de-confounding 9 Genetic variants in genetic risk score 9 Definition of exposure and outcome 10 Association between platelet count and hypertension 10 Analytic approach: Genetic risk score Mendelian randomization 11 Causal assumptions 11 Statistical Analysis 12 Genetic risk score construction 12 Weighted-median model for Mendelian randomization 13 CHAPTER 3: RESULTS 15 Clinical analysis of study participants 15 Correlation analysis 15 Mendelian randomization of causality inference 16 CHAPTER 4: DISCUSSION 18 Key findings 18 Compared to the previous studies 18 Possible interpretations 19 Extra testing for causal inference 20 Strengths 21 Limitations 23 Future plan 25 Test other platelet indices 25 Complex Mendelian randomization designs with well-defined data for confirmation 25 CHAPTER 5: CONCLUSION 27 CHAPTER 6: REFERENCE 28 Appendix 32 | |
dc.language.iso | en | |
dc.title | 以孟德爾隨機化探究血小板與高血壓之因果關係 | zh_TW |
dc.title | Using Mendelian randomization method to elucidate the causal relationship between platelet and hypertension | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 松田文彥(Fumihiko Matsuda),蕭朱杏(Chu-Hsing Hsiao),林瑞祥(Jui-Hsiang Lin) | |
dc.subject.keyword | 孟德爾隨機化,遺傳風險評分,血小板數量,高血壓,台灣人體生物資料庫,因果推論, | zh_TW |
dc.subject.keyword | Mendelian randomization,genetic risk score,platelet count,hypertension,Taiwan Biobank,causal relationship, | en |
dc.relation.page | 50 | |
dc.identifier.doi | 10.6342/NTU201902915 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-19 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 1.77 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。